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SUMMARY
Background
PREVENTCD, Prevent Coeliac Disease, is an international project investi-
gating the hypothesis of possible induction of tolerance to gluten in geneti-
cally predisposed children through introducing small quantities of gluten
during the period of breastfeeding.
Aim
To summarise current knowledge on the possible relationship between early
feeding practices and the risk of coeliac disease (CD).
Methods
The Cochrane Library, MEDLINE, and EMBASE databases were searched
in May 2011, and the search was updated in January 2012, and again in
July 2012.
Results
Breastfeeding (BF) and CD: some studies show a protective effect of BF, while
others show no effect. No studies have shown a long-term preventive effect.
BF at the time of gluten introduction and CD: Results from a meta-analysis of
ﬁve observational case-control studies suggest that BF at gluten introduction
is associated with a lower risk of CD compared with formula feeding. It is
unclear whether BF provides a permanent protection or only delays the onset
of CD. Timing of gluten introduction: The data suggest that both early
( 4 months) and late ( 7 months) introduction of gluten may increase the
risk of CD. Amount of gluten at weaning (and later) and CD: One incident
case-referent study documented that the introduction of gluten in large
amounts compared with small or medium amounts increased the risk of CD.
Conclusions
In the absence of clear evidence, in order to decrease the risk of later coeliac
disease, it is reasonable to avoid both early (<4 months) and late
( 7 months) introduction of gluten, and to introduce gluten while the infant
is still being breastfed. Future studies may clarify the remaining uncertainties.
Aliment Pharmacol Ther 2012; 36: 607–618
ª 2012 Blackwell Publishing Ltd 607
doi:10.1111/apt.12023
Alimentary Pharmacology and Therapeutics
INTRODUCTION
Coeliac disease (CD) has been recently deﬁned by the
European Society for Paediatric Gastroenterology, Hepatol-
ogy and Nutrition (ESPGHAN) as ‘an immune-mediated
systemic disorder elicited by gluten and related prolamines
in genetically susceptible individuals and characterized by
the presence of a variable combination of gluten-dependent
clinical manifestations, CD-speciﬁc antibodies, HLA-DQ2
or HLA-DQ8 haplotypes, and enteropathy. CD-speciﬁc
antibodies comprise autoantibodies against TG2 (anti-
TG2), including endomysial antibodies (EMA), and antibod-
ies against deamidated forms of gliadin peptides (DGP)’.1
The incidence of CD is as high as 0.5–1.6% in the gen-
eral population in Europe and North America.2 Higher
rates are reported in ﬁrst-degree relatives of patients with
CD, patients with autoimmune diseases such as type 1
diabetes or autoimmune thyroid disease, patients with
some chromosomal aberration disorders (e.g. Down syn-
drome, Turner syndrome, Williams syndrome), and
patients with selective IgA deﬁciency. The course of CD
may be symptomatic with the occurrence of gastrointesti-
nal and nongastrointestinal symptoms. However, CD also
may develop as an asymptomatic disease.1 A lifelong,
gluten-free diet introduced only when a conclusive diag-
nosis has been made is the recommended treatment.
Recently, key stakeholders representing a wide range
of knowledge related to CD concluded that the option of
primary prevention should be fully explored, which
requires combined epidemiological, clinical and basic
scientiﬁc research efforts. In particular, a great deal of
attention should be focused on the relationship between
early nutrition and later development of CD, particularly
on the timing and circumstances of gluten introduction.3
PREVENTCD, Prevent Coeliac Disease (http://www.
preventcd.com), is an international project, sponsored by
the European Union 6th Framework Programme. The aim
of this project is to investigate the hypothesis of possible
induction of tolerance to gluten in genetically predisposed
children through the introduction of small quantities of
gluten during the period of breastfeeding. The pivotal
objective of the project is to signiﬁcantly reduce the
number of people suffering from CD in Europe by
developing primary prevention strategies. To achieve this,
PREVENTCD involved the following areas of research in
relation to CD development: (i) infant feeding, especially
breastfeeding and gluten introduction (based on a rando-
mised, double-blind, controlled trial involving high-risk
infants and the Food Frequency Questionnaire as well as a
Swedish CD screening study among 12-year-old children
from two population cohorts that differ with respect to
infant feeding); (ii) immunological response to gluten
introduction; and (iii) genetic factors (both HLA and non-
HLA alleles). A detailed description of each study ﬁeld has
been published separately.4–7 Revision of the current Euro-
pean guidelines for early nutrition to prevent CD is the
ﬁnal objective of PREVENTCD. This, however, can only
be achieved when all data are analysed. The analysis of all
data will be feasible only after 2013 when all infants
recruited into the intervention study will have reached
3 years of age, the code will have been broken, and thus,
the study unblinded.
The purpose of this report developed by PREVENTCD
investigators is to summarise current knowledge concern-
ing the possible relationship between early feeding
practices and the risk of developing CD. In particular, a
systematic review was designed to answer the following
clinical questions grouped into four categories important
for making future recommendations:
(i) Breastfeeding (BF) and CD (Does any BF reduce the
risk of developing CD in early childhood? Is there a differ-
ence between any or exclusive BF in regard to risk reduction?
Is the duration of BF related to the risk of developing CD?).
(ii) BF at the time of gluten introduction and CD (Is
gluten consumption while being breastfed important for
risk reduction?).
(iii) Timing of gluten introduction (Is age of gluten
introduction important to the risk of developing CD?).
(iv) Amount of gluten at weaning (and later) and CD
(Is the amount of gluten ingested an independent risk
factor for the development of CD in early childhood?
Is there a threshold level of gluten consumption for
developing CD in early childhood?).
In addition, we analysed whether manipulation of the
intestinal microbiota through the administration of micro-
bial supplements (probiotics) and/or substrates (prebiot-
ics) has an effect on the risk of CD. This was based on
recent studies suggesting that aberrant development and
maturity of the gut microbiota is among the environmen-
tal factors to be associated with CD.8–11
An update of this systematic review together with an
update of current recommendations is planned immediately
after ﬁndings from PREVENTCD are available.
MATERIALS AND METHODS
The systematic review of the literature was initially
performed in May 2011 and was updated in January 2012,
and again in July 2012. The electronic searches were based
on the content of the Cochrane Central Register of
Controlled Trials (CENTRAL, the Cochrane Library),
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MEDLINE and EMBASE. Several searches were performed
separately for all categories of clinical questions listed
above. In addition, the reference lists from identiﬁed studies
and key review articles were searched. Researchers working
in the ﬁeld, primarily partners in PREVENTCD, were con-
tacted for any unpublished data. Certain publication types
(i.e. letters to the editor, abstracts, proceedings from scien-
tiﬁc meetings) were excluded, unless a full set of data was
available from the authors. No language restriction was
imposed. The search was carried out independently by two
reviewers (AC, MP). The most recent update was carried
out by one reviewer (HS). The following search terms were
used separately for each clinical question:
(i) celiac or coeliac or CD or sprue or gluten enteropathy.
(ii) breast-feeding or breastfeeding or breast feeding or
breastfed.
(iii) child or childhood or children or child* or infant*
or toddler or early.
(iv) gluten and (timing or time) and introduction.
(v) amount or quantity.
(vi) probiotic* or prebiotic*.
Types of studies
Studies of any design, preferentially randomised controlled
trials (RCTs), investigating the potential association
between early feeding practices and risk of CD were eligi-
ble for inclusion. In addition, previously published system-
atic reviews/meta-analyses were considered for inclusion.
Types of participants
Participants involved in the prospective studies had to be
infants at population risk or increased risk of developing
CD (deﬁned by HLA status, ﬁrst-degree relative with CD
or type 1 diabetes mellitus). For retrospective studies,
participants had to be children or adults with CD diag-
nosed by small bowel biopsy or presenting with positive
serology indicative of CD.
Types of intervention (interventional studies)
Interventions used had to be a gluten-containing product
meeting any deﬁnition (e.g. cereals, ﬂour or any other
foods containing gluten, preparations manufactured for
research purposes). In addition, studies that assessed the
effect of probiotics and/or prebiotics compared with
control (placebo or no treatment) were considered.
Outcome measures
The primary outcome measure was CD or the develop-
ment of CD-associated autoantibodies (i.e. anti-TG2 or
EMA). The studies should have assessed the risk of CD
in people who were:
(i) Ever breastfed compared with those never breastfed.
(ii) Exclusively breastfed compared with those receiv-
ing any human milk.
(iii) Breastfed for different periods of time (short com-
pared with long breastfeeding according to the deﬁnition
given by the authors).
(iv) Breastfed at the time of gluten introduction
compared with those who were not.
(v) Given gluten for the ﬁrst time at different ages
(early compared with late introduction according to the
deﬁnition given by the authors).
(vi) Given gluten in different amounts (by any
quantity units or thresholds used by the authors).
Data collection and analysis
An initial screening of the title, abstract and keywords
of every record identiﬁed was performed. The next step
was retrieval of the full text of potentially relevant trials.
Two reviewers (AC, MP) independently assessed the
eligibility of each potentially relevant trial with the use
of inclusion criteria. If they had different opinions,
these were resolved by discussion with the third reviewer
(HS).
Assessment of methodology of included studies
The reviewers independently, but without being blinded
to the authors or journal, assessed the risk of bias in the
studies that met the inclusion criteria. For interventional
studies, The Cochrane Collaboration’s tool for assessing
risk of bias was used, which includes the following
criteria: adequacy of sequence generation, allocation
concealment and blinding of participants, personnel and
outcome assessors; incomplete outcome data are
addressed, free of selective outcome reporting and free of
other sources of bias.12 There is no tool for assessing the
quality of nonrandomised trials that would be widely
recognised as most effective.13 Again, we chose to use
The Cochrane Handbook for Systematic Reviews of
Interventions.14
Statistical methods
Although a meta-analysis of the available data was
initially planned, after data collection it turned out not
to be feasible for any of the outcomes. The reason was
the different deﬁnitions of outcomes of interest used by
different authors. For example, breastfeeding was deﬁned
as the duration of breastfeeding by some authors or time
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intervals when it was ceased by others. In addition, the
timing of gluten introduction was reported as either a
point in time or a certain time interval. Whenever possi-
ble, we report the binary measure for individual studies
as the odds ratio (OR) between the experimental and
control groups with 95% CI or as the hazard ratio (HR),
as presented by the authors of individual trials. Continu-
ous outcomes are presented as the mean with standard
deviation (s.d.) or the median with ranges, again as
reported by the authors. For outcomes of interest that
have previously been reviewed systematically, we have
summarised the ﬁndings from those reviews.
RESULTS
Description of studies included in the review
Twenty-eight potentially eligible studies were initially
identiﬁed. During a repeat search (July 2012), one addi-
tional study was identiﬁed. Eventually, 12 studies were
included, the characteristics of which are summarised
in Table S1.8, 15–25 Eleven included trials were of obser-
vational design. Two studies21, 25 used healthy children
as controls. In those two studies, CD, based on positive
serology but not biopsy-proven CD, was assessed.
Three of the studies were cohort studies. Studies by
Norris et al.21 and Ziegler et al.25 followed children at
genetic risk of CD or type 1 diabetes. Welander et al.24
performed a population-based cohort study. Only one
interventional study was identiﬁed.8 This study
recruited 34 infants at risk of CD (positive for HLA
DQ2 and/or HLA DQ8). The families of four of these
infants refused to participate. Therefore, from 6 to
12 months of age, 30 infants were randomly assigned
to receive either a gluten-free diet (delayed exposure
group, n = 13) or a gluten-containing diet from
6 months of age (early exposure group, n = 17). In all
infants, a normal, gluten-containing diet was adminis-
tered at 12 months. While the study was reported as a
randomised, double-blinded trial, it lacked adequate
information to assess the overall risk of bias (unclear
randomisation, allocation concealment and blinding).
The researchers assessed CD development and serologi-
cal evaluation. In addition, the stool samples of eight
randomly selected infants in each group were collected
for microbiota and metabolome analyses from day 7 to
24 months of age.
The protocol of one ongoing multicenter, randomised,
double-blind, placebo-controlled study exploring the role
of early infant feeding on CD development (PREVENTCD)
has been published.4
In addition, two systematic reviews were identiﬁed.
Akobeng et al.26 conducted a systematic review of the
literature that explored the effect of BF compared with no
BF, the effect of the duration of BF and the effect of BF at
the time of the introduction of dietary gluten. The MED-
LINE, EMBASE and CINAHL databases were searched
(until May 2004) as well as reference lists. No language
restrictions were applied. An attempt to identify unpub-
lished data was made. Two reviewers independently
assessed the methodological quality of the included trials
using the Critical Appraisal Skills Programme tool for case-
control studies. Studies were assigned an overall rating of A
(low risk of bias), B (moderate risk of bias) or C (high risk
of bias). A total of six case-control studies,15, 16, 18–20, 22 all
of which were also identiﬁed by us, were included. All
included studies were graded B. To assess the effect of BF at
the time of gluten introduction, a meta-analysis of all
included case-control studies was performed using a ﬁxed
effect model. For other outcomes, a meta-analysis was not
feasible, so only a systematic review was performed.
The second systematic review by Nash et al.27 was
aimed at determining if exclusive BF reduced the risk of
CD. The MEDLINE, EMBASE and CINAHL, databases
were searched (presumably in 2003) for cohort studies
and case-control studies, if published in English and
available in the library of the reviewer. No attempt was
made to identify unpublished data. The methodological
quality of included trials was described, although not for-
mally assessed. Three case-control trials16, 19, 22 were
included in the review.
For the current review, 16 publications were excluded
(Table S2). Among them, four studies were of retrospec-
tive design with no control group, 10 were reviews and
one was a letter without a description of the methodol-
ogy provided. In addition, one trial was not included
because it explored the changing practices of early infant
feeding in relation to the incidence of CD.
A summary of the results for all clinical questions is
presented in Tables 1–3.
Breastfeeding and coeliac disease
Exclusive breastfeeding vs. any breastfeeding. One sys-
tematic review27 assessed the possible relationship
between exclusive BF and a reduction in the risk of CD.
Three case-control studies16, 19, 22 were included in the
review (n = 2935; 560 cases and 2375 controls). All of
the studies were retrospective and open to recall bias.
There was no evidence suggesting that exclusive BF com-
pared with formula or mixed feeding either reduces the
risk of CD or delays the onset of symptoms.
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Ever breastfed vs. never breastfed. Two studies reported
this exposure.17, 22 In the study by Decker et al.,17 more
children with CD were ever breastfed (OR 1.99, 95% CI
1.12–3.51; P = 0.015).17 Peters et al.22 reported a lower
risk of CD in ever-breastfed children compared with
those who were never breastfed. Moreover, the longer
the breastfeeding duration compared with no breastfeed-
ing at all, the lower the risk of CD.
Duration of breastfeeding and coeliac disease. Eleven
studies15–25 evaluated the relationship between the dura-
tion of BF and CD (Table 1). Data from six of these tri-
als15, 16, 18–20, 22 were analysed in the systematic review
by Akobeng et al.26 Based on the ﬁndings from ﬁve of
the studies, the reviewers stated that protection against
CD with longer duration of BF was reported. However,
more current evidence did not show that short-term BF
was associated with an increased risk for CD.17, 21, 23–25
With few exceptions (e.g. Welander24), most of the data
were collected retrospectively.
Breastfeeding at the time of gluten introduction and
coeliac disease
Five studies15, 18, 20–22 explored the role of BF at the
time when gluten-containing products were introduced
into the infants’ diet (Table 2). Three of them reported a
signiﬁcantly reduced risk of CD in children who were
breastfed when they started receiving gluten. In one
small study15 and in one large prospective trial,21 no
statistically signiﬁcant difference was observed between
the case and control groups. In addition to the prospec-
tive design, one additional feature of the study by Nor-
ris21 that differentiates it from earlier studies is that it
focused on children at high risk for CD (in a cohort
originally designed to study children at high risk of
developing type 1 diabetes). All studies but the latter
study21 were considered in the meta-analysis by Akobeng
et al.26 In the latter meta-analysis, the pooled risk for
developing CD in children breastfed compared with
those who were not breastfed at the time of gluten intro-
duction was reduced by almost 50% (OR 0.48; 95% CI
0.40–0.59).
Timing of gluten introduction
Six studies18, 20–22, 24, 25 explored whether the timing of
the ﬁrst introduction of gluten-containing products may
inﬂuence the risk of CD (Table 3). Most of these deﬁned
the moment of gluten introduction as a time interval (e.
g. <3 months or 7–8 months). Therefore, the deﬁnitions
used by the authors were different, thus, results were dif-
ﬁcult to compare.
Out of ﬁve trials, two21, 22 reported a signiﬁcantly
increased risk of developing CD (or CD-associated
autoantibodies) related to the timing of gluten introduc-
tion. The prospective, observational, cohort study by Nor-
ris et al.21 revealed that both early (less than 3 months)
and late (more than 7 months of age) introduction of glu-
ten to children at increased risk of CD and type 1 diabetes
mellitus was associated with an increased risk of CD. Chil-
dren exposed to gluten before 3 months of age had a ﬁve-
fold higher risk of developing CD than those with gluten
introduced between 4 and 6 months of age. The risk was
slightly higher when gluten was ﬁrst given at the age of
7 months or later compared with when it was ﬁrst given
at 4–6 months of age (see Table 3 for details). The
strength of this study is its prospective design; however, it
Table 2 | Breastfeeding at the time of gluten introduction
Reference Design OR Effect Strengths/Limitations
Akobeng 200626 Meta-analysis of
case-control
studies
Ascher 1.54 (0.27–10.56) No effect Not clear whether BF
provides long-term
protection or just
delays the symptoms.*
Falth-Magnusson 0.35 (0.17–0.66) Protective
Ivarsson 0.5 (0.4–0.64) Protective
Peters 0.46 (0.27–0.78) Protective
Pooled 0.48 (0.4–0.59) Protective
Norris 200521 Prospective
observational
study
HR 1.32 (0.76–2.28) No effect Prospective design; however,
small number of subjects in
whom the outcome measures
occurred; use of CD
autoimmunity as a surrogate
for biopsy-diagnosed CD.
* Comment applies to all studies listed under Akobeng 2006.
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Table 3 | Time of gluten introduction
Reference Age Measure Effect size Effect Limitations
Falth-Magnusson
199618
Age of gluten introduction in CD infants 6 months (mean: 6;
range: 4–7) compared with 6.1 months (6; 4–10) for reference
infants.
No effect
Ivarsson 200220 1–4 months Adjusted OR for
breastfeeding and
gluten introduction
1 Reference Introduction between
5–6 months dominated
(CD cases 82% and
referents 73%), thus
the other groups are
the ones that cause
uncertainty*
5–6 months 1.4 (0.87–2.4) No effect
7–12 months 0.76 (0.41–1.4) No effect
Norris 200521 1–3 months Unadjusted HR 2.94 (0.83–10.4) Predisposing Small number of
subjects in whom the
outcome measure
occurred; the use
of CD autoantibodies
as a surrogate for
biopsy-diagnosed
CD; the amount of
gluten during
introduction not
assessed.
Time of gluten
introduction in
reference population
quite young; most
EU countries at that
time advised
>6 months*
4–6 months 1.0 (reference) Reference
 7 months 1.78 (0.92–3.42) Predisposing
Peters 200122 >3 months vs.
 3 months
Adjusted OR 0.72 (0.29–1.79) No effect
 3 months 1.0 No effect
>3 to 4 months 0.52 (0.18–1.44) No effect
>4 to  5 months 1.21 (0.4–3.68) No effect
>5 months 0.72 (0.28–1.85) No effect
Welander 201024 0–2 months Unadjusted HR Not estimated –
3–4 months 1.0 (0.3–3.3) No effect
5–6 months 1.0 (reference) Reference
7–8 months 1.1 (0.6–2.0) No effect
9–10 months Not estimated –
11–12 months Not estimated –
Ziegler 200325  3 months Unadjusted HR 2.3 (0.3–18.2) No effect Not CD, but the
development
of CD-associated
autoantibodies
was the outcome*
3.1–6 months 1 Reference
>6 months 0.7 (0.3–1.8) No effect
Unknown 1.0 (0.3–2.6) No effect
* Comment applies to all age groups.
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has several limitations (e.g. the small number of subjects
in whom the outcome measure occurred, the use of CD
autoantibodies as a surrogate for biopsy-diagnosed CD).
Moreover, the amount of gluten given during introduction
was not assessed, thus, remains as a potential confounder.
According to Peters et al.22, no difference was found in
the risk of CD depending on the time of gluten introduc-
tion for the majority of time intervals they deﬁned. How-
ever, when adjusted for age, sex, number of inhabitants of
residence and family predisposition to CD, the OR for
>4 months vs.  4 months was 0.66 (95% CI 0.44–1.00).
The remaining studies did not show a relationship
between the timing of gluten introduction and the risk of
developing CD.
In the only included RCT,8 the researchers reported
data on CD development and serological evaluation in a
subgroup of eight infants in each study group. At
24 months, no signiﬁcant difference was found in CD
development, deﬁned by the appearance of CD anti-
tissue transglutaminase antibodies, onset of CD-related
symptoms and/or evidence of autoimmune enteropathy,
in the delayed exposure to gluten group compared with
the early exposure to gluten group (0/8 vs. 1/8, respec-
tively, relative risk 0.33, 95% CI 0.02–7.1). Similarly,
there was no difference in anti-gliadin antibodies of
the class IgG between groups except at 12 mo when the
difference between the delayed exposure to gluten group
compared with the early exposure to gluten group was
of borderline statistical signiﬁcance (0/12 vs. 8/13,
relative risk 0.06 (95% CI 0.00–0.99).
Amount of gluten at weaning (and later) and CD
Only one study20 analysed the amount of gluten that
children received. In children younger than 2 years of
age, the risk of developing CD was greater when gluten
was introduced into the diet in large amounts than when
introduced in small or medium amounts (adjusted OR
1.5, 95% CI 1.1–2.1). In older children, there was no
effect.
Administration of probiotics and/or prebiotics
No studies that have addressed these issues were identiﬁed.
DISCUSSION
Breastfeeding and CD
There are studies that show a protective effect of breast-
feeding as well as studies that show no effect. No studies
have shown a long-term preventive effect of BF. Thus,
whether or not BF protects or delays the clinical presenta-
tion of CD remains controversial. Despite the fact that
there is controversy in the literature, this does not mean
that breastfeeding does not have signiﬁcant effects in pre-
venting CD. Rather, this is more likely a reﬂection of the
methodological inadequacy of investigating breastfeeding
in ways that take into account all the complexity of inter-
actions. The methodological problems likely to contribute
to inconsistent results include ﬁrst, the inability to rando-
mise and blind. In general, the studies on breastfeeding are
nonrandomised, retrospective or observational in design
and, thus, produce inconclusive results. Second, the retro-
spective design of many studies addressing the association
between breastfeeding and CD and the potential for
parental recall bias impose methodological challenges.
One may overcome the problem of parental recall bias by
obtaining prospective feeding histories. Third, most of the
studies that have examined the effect of breastfeeding on
CD were carried out in unselected birth cohorts with
regard to CD risk. Only a limited number of studies have
assessed the effect of breastfeeding in high-risk infants.
Inconsistencies may be also due to imprecise deﬁnitions of
the intervention. Fourth, many studies do not make the
distinction between ‘exclusive breastfeeding’ and ‘any
breastfeeding’. Finally, ideally, the diagnosis of CD should
be based on widely agreed-upon criteria. However, in
some of the studies on the effect of breastfeeding, CD-
speciﬁc serology, not biopsy-proven CD, was assessed,
making comparisons between the studies difﬁcult.
The exact mechanisms that underlie the relationship
between breastfeeding and possible protection against
CD remain uncertain. Likely explanations have been
extensively discussed in earlier studies and reviews.28 In
brief, it has been postulated that breast milk contains
factors such as secretory IgA antibodies, lactoferrin, lyso-
zyme and others that contribute to passive immunity.
These factors may contribute to the reduced number of
gastrointestinal infections potentially contributing to the
pathogenesis of CD by increasing gut permeability or
alterations to the immune system.29 Moreover, human
milk contains cytokines such as down-regulatory trans-
forming growth factor b that may inﬂuence immune
development and the type of immune response. When
studying the interaction between breastfeeding and CD,
the complex interactions between intestinal immunology,
gut microbiome, genetic predisposition, gluten consump-
tion and breastfeeding should be considered. In addition,
human milk contains gluten in small quantities30, 31; this
can perhaps induce tolerance to gluten as it has been
suggested for other antigens.32 Future studies are needed
to fully understand the relationship between BF and CD.
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BF at the time of gluten introduction and CD
Results from a meta-analysis of ﬁve observational case-
control studies suggest that BF at the time of gluten
introduction is associated with a lower risk of CD com-
pared with formula feeding. However, the majority of
these studies were based on retrospectively collected
feeding data. It is unclear whether BF provides a perma-
nent protection or only delays the onset of CD. Available
data are insufﬁcient to prove causality. Moreover, one
more recent prospective study found no effect of BF at
the time of gluten introduction on CD autoimmunity,
but the effect on biopsy-proven CD is unknown.21
Timing of gluten introduction
The role of age at gluten introduction with respect to the
risk of CD is unclear. The data from observational stud-
ies suggest that early ( 3 months after birth), and pos-
sibly late ( 7 months after birth), introduction of
gluten may be associated with an increased risk of CD
and probably should be avoided. The only interventional
study suggested that delayed introduction of gluten
(12 months of age) may be beneﬁcial. However, the
results of this RCT should be viewed with caution given
the small sample size and unclear risk of bias.
Amount of gluten at weaning (and later) and CD
The results of one incident case-referent study documented
that the introduction of gluten in large amounts compared
with small or medium amounts increased the risk of CD.20
These data support previous ﬁndings from the same country,
i.e. Sweden. In the mid 1980s, this country experienced an
epidemic of CD in children younger than 2 years of age. A
twofold increase in the average daily consumption of gluten
was followed by a fourfold rise in the incidence of CD.When
gluten consumption decreased 10 years later, an abrupt fall
in the incidence of CD was observed.6 However, also the rec-
ommended age for gluten introduction was changed
preceding both the start of the epidemic (from 4 to
6 months) and the end (back to 4 months), which changed
the proportion of infants introduced to gluten while being
breastfed. Still, the amount of gluten is likely to be a contrib-
uting risk factor for CD. Whether this is a dose–response or
a threshold effect remains unknown. However, more
recently, a quantitative model of CD development was sug-
gested and an HLA-DQ2 gene dose effect in the develop-
ment of CD was proposed.33An interaction between HLA-
DQ2 expression and the available number of T-cell stimula-
tory gluten peptides was documented. In particular, the
strongly increased risk of CD development for HLA-DQ2.5
homozygous and HLA-DQ2.2/2.5 heterozygous individuals
was found, while HLA-DQ2.5/non-DQ2 heterozygous indi-
viduals had only a slightly increased risk of CD. If the thresh-
old effect is valid, the amount of gluten needed to initiate the
immunological response may be different in HLA-DQ2
homozygous and heterozygous individuals. On the other
hand, a lack of in vivo/ex vivo evidence of gluten epitope
diversity being greater in HLA DQ2 homozygotes with CD,
and considering that information about children and gluten-
speciﬁc T cells is limited to a single study, call for caution in
the interpretation. Furthermore, a recent study supports
greater T-cell epitope diversity in HLA DQ2/DQ8 + hetero-
zygotes than in HLA DQ2 + individuals because of the efﬁ-
cient transdimer presentation of gluten peptides. However,
HLA DQ2/DQ8 + individuals are at no greater risk of CD
than HLA DQ2 + heterozygotes, suggesting epitope diver-
sity is not clearly inﬂuencing susceptibility.34
Administration of probiotics and/or prebiotics
In other conditions characterised by a deranged immune
response of the mucosal immune system, attention has
been given to the possible role of manipulation of the gut
microbiota. Probiotics and/or prebiotics have been sug-
gested to inﬂuence immune development and the type of
immune response. Therefore, it could be envisaged that
probiotics/prebiotics may inﬂuence the type of immune
reactivity to gluten in subjects with CD. The composition
of the gut microbiota differs between individuals with CD
and healthy individuals with respect to phylogenetic diver-
sity and abundance of microbial taxa. For example, some
of the most recent data, albeit obtained from a relatively
small group of subjects, have shown that gut microbiota
of infants at risk for CD exhibited reduced proportions of
Bacteroidetes and an increased proportion of Firmicutes
compared with those with a nonselected genetic back-
ground.8 However, other studies have reported a higher
abundance of Bacteroidetes.9, 11 We were unable to iden-
tify intervention studies on supplementation of pre/probi-
otics and prevention of CD. Future studies need to
establish the exact role of gut microbiota in the develop-
ment of CD. If so, strategies to manipulate and reshape
gut microbiota to a more healthy type may be of interest.
CONCLUSIONS
A summary of recommendations made for gluten introduc-
tion in the countries involved in the PREVENTCD project
is presented in Table 4. With regard to the scientiﬁc
authorities, the Committee on Nutrition of the European
Society for Paediatric Gastroenterology, Hepatology and
Nutrition (ESPGHAN) recommends that it is prudent to
avoid both early (less than 4 months) and late (7 or more
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months) introduction of gluten and to introduce gluten while
the infant is still being breastfed.35 The Committee considers
that such a strategy may reduce not only the risk of CD, but
also the risks of type 1 diabetes mellitus and wheat allergy.
The American Academy of Pediatrics (AAP) recommends
that complementary foods can be introduced between 4 and
6 months of age; gluten-containing foods should be intro-
duced while the infant is receiving only breast milk and not
infant formula or other bovine milk products.36 In the absence
of clear evidence, it is reasonable to follow recommenda-
tions made by scientiﬁc organisations such as ESPGHAN
while awaiting results of future studies (e.g. PREVENTCD
project) that will shed light on the remaining uncertainties.
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APPENDIX 1. THE PREVENTCD STUDY GROUP
Belgium: Association of European Coeliac Societies
(AOECS): C Scerri, T Koltai; Croatia: University Chil-
dren’s Hospital Zagreb: S Kolaček, Z Mišak, S Abdović;
Germany: Hauner Children’s Hospital, University of
Munich Medical Centre, Munich, Germany: S Koletzko, G
Osiander, K Werkstetter; Phadia GmbH: E Mummert;
Hungary: Coeliac Disease Centre of Heim Pál Children’s
Hospital: IR Korponay-Szabo, J Gyimesi; Israel: M
Berant Rambam Health Care Campus, Haifa, Israel;
Schneider Children’s Medical Centre, Sackler Faculty of
Medicine, Tel-Aviv University: R Shamir, C Hartman;
Italy: Eurospital SpA: E Bravi, M Poles; European Labo-
ratory for the Investigation of Food-Induced Diseases
(ELFID), University Federico II: R Auricchio, G Limong-
elli, L Greco, R Troncone; Spedali Civili, Brescia: V Vil-
lanacci; the Netherlands: Danone Research BV: JG
Bindels; Leiden University Medical Centre: R Brand, B
Funke Kupper, CE Hogen Esch, EG Hopman, F Koning,
EMC Kooy-Winkelaar, MC te Marvelde, H Putter, E
Stoopman Groningen: University of Groningen, Univer-
sity Medical Center Groningen, Department of Genetics,
Groningen: J. Romanos, C. Wijmenga, S. Jankipersadsing;
Norway: University of Oslo: LM Sollid, M Ráki; Poland:
The Medical University of Warsaw: A Chmielewska, P
Dziechciarz, M Piescik-Lech, H Szajewska; Department
and Clinic of Pediatrics, Allergology and Gastroenterolo-
gy, Medical University: A. Szaﬂarska-Szczepanik; Spain:
Hospital Universitaride Sant Joan de Reus/Universitat
Rovira i Virgili: G Castillejo, J Escribano; Institutode
Biomedicina de Valencia (CSIC): A Capilla and Hospital
Sant Joan de Deu Barcelona: V Varea; La Fe University
Hospital: C Ribes-Koninckx, P Crespo; La Paz University
Hospital: E Martinez, I Polanco; Sweden: Linköping Uni-
versity: L Högberg, L Stenhammar; Lund University: A
Carlsson, C Webb; Norrtälje Hospital: S Hammarroth;
Umeå University: O Hernell, A Ivarsson, C Lagerqvist,
A Myléus, K Nordyke, F Norström, O Sandström, S
Wall; Växjö Hospital: E. Karlsson.
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